Recipharm completes strategic acquisition in India

Contract development and manufacturing organisation, Recipharm, has announced that it has completed the acquisition of biopharma organisation Kemwell’s pharmaceutical business, located in Bengaluru India.

The company stated that the acquisition will significantly expand its position within emerging markets. It will also represent a major extension of Recipharm’s capabilities in India by providing access to increased development operation.

Recipharm state that the acquisition adds US FDA and EU approved manufacturing options and further strengthens the company’s business model.

Thomas Eldered, CEO of Recipharm AB said “I am pleased we have now finally completed this important acquisition. We are now in a position to offer our customers access to cost effective development and manufacturing capabilities able to serve international markets including the US. These acquisitions are already showing great promise and I am pleased the current managing director, Anurag Bagaria, and VP Corporate Development, Karan Bagaria, will continue in their current positions going